Combination therapies for MPNSTs targeting RABL6A-RB1 signaling

Jordan L. Kohlmeyer; David J. Gordon; Munir R. Tanas; Rebecca D. Dodd; Varun Monga; Benjamin W. Darbro; Dawn E. Quelle

doi:10.18632/oncotarget.27862

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Combination therapies for MPNSTs targeting RABL6A-RB1 signaling

Jordan L. Kohlmeyer, David J. Gordon, Munir R. Tanas, Rebecca D. Dodd, Varun Monga, Benjamin W. Darbro and Dawn E. Quelle _

PDF | Full Text | How to cite

Oncotarget. 2021; 12:10-14. https://doi.org/10.18632/oncotarget.27862

Metrics: PDF 1372 views | Full Text 2310 views | ?

Abstract

Jordan L. Kohlmeyer1^,2, David J. Gordon3^,6, Munir R. Tanas1^,4^,6, Rebecca D. Dodd1^,5^,6, Varun Monga5^,6, Benjamin W. Darbro3^,6 and Dawn E. Quelle1^,2^,3^,6

1 Molecular Medicine Graduate Program, University of Iowa, Iowa City, Iowa, USA

2 Department of Neuroscience and Pharmacology, University of Iowa, Iowa City, Iowa, USA

3 Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA

4 Department of Pathology, University of Iowa, Iowa City, Iowa, USA

5 Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA

6 Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA

Correspondence to:

Dawn E. Quelle,

email:

[email protected]

Keywords: MPNST; RABL6A-RB1 signaling; CDK4/6 and MEK inhibitors; Ras; targeted cancer therapy

Received: December 15, 2020 Accepted: December 16, 2020 Published: January 05, 2021

Copyright: © 2021 Kohlmeyer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Precision medicine relies on a detailed molecular understanding of disease pathogenesis. Here, we consider urgently needed therapeutic options for malignant peripheral nerve sheath tumors (MPNSTs) based on emerging insights into druggable pathway alterations found to drive this deadly cancer. Recent observations demonstrate an essential role for an oncogenic GTPase, RABL6A, in promoting MPNST progression through hyperactivation of cyclin-dependent kinases (CDKs) and inactivation of the retinoblastoma (RB1) tumor suppressor. Monotherapies with CDK4/6 inhibitors have shown limited efficacy and durability in pre-clinical studies of MPNSTs and in clinical studies of other tumors. Therefore, we discuss the rationale and clinical benefits of inhibiting multiple RABL6A effectors, particularly CDK4/6 and MEK kinases, in targeted combination therapies suitable for MPNSTs and other Ras-driven malignancies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27862

Publication Alerts

Research Perspectives:

Combination therapies for MPNSTs targeting RABL6A-RB1 signaling

Abstract